Metabolomics Biomarker Market Revenue to Attain USD 10.85 Bn by 2035

Published: 27 Feb 2026

Author: Precedence Research

Share:

Metabolomics Biomarker Market Revenue and Trends 2026 to 2035

The global metabolomics biomarker market revenue was valued at USD 3.30 billion in 2025 and is expected to attain around USD 10.85 billion by 2035, growing at a CAGR of 12.64% during forecast period.The market is rapidly expanding due to the growing demand for precision medicine amid the chronic disease burden and significant investment in biomarker discovery R&D.

What are the Major Factors Driving the Metabolomics Biomarker Market?

The market is rapidly expanding due to factors such as rising incidence of chronic diseases, R&D funding and investment, and a rapid shift toward multiomics development, supported by government funding. Technological advancements in analytical tools such as mass spectrometry and NMR, along with AI integration for data analysis, are further supporting market expansion. The increasing prevalence of diabetes, obesity, and cardiovascular diseases necessitates early diagnosis and treatment, which has led to the rapid expansion of metabolic biomarkers. In addition, combining metabolic with genomics and proteomics enables a more comprehensive understanding of biological systems. Significant investment by public and private institutions in drug discovery and biomarker development is a key driver of market growth.

Segments Insights

• By Type, The targeted metabolomics segment held the largest market share in 2025, owing to its significantly high fidelity and widespread application in clinical settings. It is mainly used to measure pre-established metabolites, which are highly crucial for drug development and clinical validation assessments within closed environments.
• By Application, The drug discovery segment held the largest market share in 2025, as several companies are increasingly prioritizing the precise identification of biomarkers during target validation and the determination of toxicity level. Metabolomics offers a deeper understanding of disease pathways and how a drug is interacting that allows companies to select precise candidates.

Regional Insights

North America held the largest share of the metabolomics biomarker market in 2025 due to several key factors, including substantial investments and funding in research and development, advanced healthcare infrastructure to address the growing burden of chronic diseases, and supportive government regulations. Government institutions such as the National Institutes of Health (NIH), along with private biotechnology and pharmaceutical companies, are increasingly adopting metabolomics technologies for the diagnosis and research of oncology and cardiovascular diseases (CVDs).

Asia Pacific is expected to register the fastest CAGR during the foreseeable period, driven by the high prevalence of chronic diseases, substantial investments by leading countries in healthcare R&D, and a growing shift toward personalized medicine. This transition, particularly in oncology, requires patient-centric metabolomics data to enable precise diagnosis, targeted therapies, and improved treatment outcomes.

Metabolomics Biomarker Market Coverage

Recent Development

• In February 2026, the global leader in providing metabolomics solutions, Metabolon, Inc., aiming to provide advancements in life science research, diagnostic, and therapeutic development, announced its industry-leading global metabolomics platform, which was previously leveraged by researchers from Kite from Gilead company for an extensive metabolic study in the context of CAR T-cell therapy.(Source: https://www.prnewswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7796

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344